As you know, I’ve been working hard to get all of our 2013 stem cell registry data out. This one reflects our Regenexx-SD knee stem cell research functional data. My goal is also to get it into easy to understand infographics so that patients can comprehend what it does and doesn’t tell us. Above is the LEFS (Lower Extremity Functional Scale) data from our knee arthritis patients treated with stem cell injections. I’ve previously reported % improvement data, so this is just the functional questionnaire version of the same data. Functional questionnaires ask things like how well you can walk, run, climb stairs, etc… Note that the improvements are highly statistically significant. This week I’ll be releasing more data on hips and hand/wrist. I’m still working my way through shoulder and ankle/foot, so those may take a while as they have many subsets of patient types. Again, these results only apply to the proprietary Regenexx-SD treatment protocol and not every stem cell huckster on the Internet! As always, click on the thumbnail above or here to see the full PDF.
Does having a few extra pounds reduce your chances of a successful outcome with the Regenexx-SD stem cell procedure for knee arthritis? For years, we have followed the same guidelines as the knee micro fracture procedure, where higher BMI (Body Mass Index) generally means worse outcomes. However, while our Regenexx-C cultured stem cell procedure data showed less robust cell growth for heavier men and women, that didn’t translate to a worse clinical outcome for heavier patients (see below). Despite this, we didn’t know how the Regenexx-SD knee procedure would fare. Would it also be agnostic toward body weight or would it follow the outcomes of many knee surgery procedures where heavier patients had less robust results? I am pleased to report this morning that our knee stem cell research on Regenexx-SD data for knee arthritis follows the same metrics as the Regenexx-C procedure in that heavier patients had no different results than lighter patients. Again, we have dissuaded many heavier patients from undergoing the same day procedure because we weren’t sure which way this data would turn out and that was the right thing to do. In addition, it’s important to note that we have no idea if the same will hold true for other stem cell procedures that use fat or bedside machines, only that our registry data is clear for our proprietary knee stem cell procedure. The upshot? if you have some extra pounds, while we may recommend dietary changes to help your cells, those extra pounds don’t seem to hurt your chances of a good outcome. Click here or the thumbnail above for the PDF.
RegenexxCayman is an independently owned and operated medical services provider operating exclusively in the Cayman Islands and is not part of or affiliated with the Centeno-Schultz Clinic or any U.S. Regenexx Network provider. The Regenexx-C procedure licensed by RegenexxCayman is not approved by the U.S. FDA for use in the United States.
In keeping with the Regenexx-SD infographic I released yesterday, I thought I’d take our knee stem cell research data on Regenexx-C and create the same kind of document. As stated before, this is registry data, in this case it’s been published in the peer reviewed literature. Note that despite 50% more knee replacement candidates being in this group of knee arthritis patients treated with the Regenexx-C cultured stem cell procedure, this outcome data still looks better than Regenexx-SD. This is also what we have observed clinically, patients with more severe arthritis do better with Regenexx-C than -SD. A bigger version of this can be found at this link…
Formula 1 Regenexx Dubai? As a break from all the serious blogging, here are some great pics of our Research Director who was in Dubai recently presenting knee and hip stem cell data at an international conference. He got the amazing opportunity to drive a formula-1 car and also sported his Regenexx t-shirt for the cameras. If you get a chance to visit our Colorado medical practice, we’re now starting to line the walls with our published research papers on stem cells in addition to the athlete pictures already there. Here’s to many more fast miles for the Regenexx team!
We’re one of the only clinics in the United States offering stem cell therapies that has a research department and uses a registry to track patients and publish the results of our patients. To that end, we just published another study as a safety update for Regenexx-C stem cell therapy as well as knee outcome data for severe knee arthritis patients. This complication study tracked 339 patients for up to 4 years (our last study looked at 227 patients for 2-3 years) and involved over 200 research grade MRI’s of 50 patients to ensure that the cultured stem cells had produced no problems. In addition, this new study publishes additional knee data showing very good results when all patients are factored in (not just the patients that did well with stem cell therapy, but also the patients that didn’t respond). We’re proud of our Regenexx stem cell research and our commitment to research the Regenexx family of procedures.
It seems like the number of U.S. doctors offering some kind of “stem cell therapy” for knees and other joints is exploding, most using shaker kits, processing in small hoods, or a bedside centrifuge. The problem is that there’s still very little real data published on human safety or efficacy of stem cell used in knees, hips, shoulder, or other joints. Since we’ve been treating orthopedic patients with their own stem cells since 2005 (not PRP which we have used as well, but stem cells) and collecting data meticulously since that time, we’ve published most of the human research in orthopedics in the U.S. to date. We’ve published case reports with MRI’s showing positive changes in knee cartilage attributed to stem cells as well other case reports showing MRI changes in the knee meniscus following stem cell treatment and in the hip after the patient’s own stem cells were injected. In addition, we’ve published the world’s largest complications reporting paper on stem cell use in orthopedics. We’ve also presented our knee and hip outcome data (221 patients) at the Orthopedic Research Society. We’ve presented our orthopedic stem cell research research at various international conferences such as the American Academy of Orthopedic Medicine, The McGowan Institute at the University of Pittsburgh, the Univeridad Catolica in Argentina, the International Cellular Medicine Society, the National Athletic Trainers Association, and will be presenting at the University of Wisconsin and the Vatican in Rome this October and November. We’re now proud to announce yet another scientific milestone, an even bigger complications reporting paper has just been accepted for scientific publication after peer review. Our first stem cell complications paper had 227 patients followed for between 3 months and 2-3 years and about 50-60 ultra-high field MRIs of the re-implant sites. Our new paper has 339 patients followed for up to 3-4 years with 210 MRIs of the places where cells were re-implanted. In addition, knee outcome data for Regenexx-C will also be published. This will include an analysis of our knee stem cell research and observations that the Regenexx-C procedure is dramatically safer than the knee replacement surgeries it helped many patients avoid. We’re in the galley proof stage on this bigger publication, so it will be a few months before it makes it into press. Also expect a paper more focused on knee/hip patient outcomes to be published sometime this year or early next, as that paper is winding it’s way through the scientific review process. The upshot? Check under the hood to see if the stem cell therapy you’re being offered has stood the test of time and peer review through scientific publication. Stem cell orthopedic treatments come in all sorts of shapes and sizes, so make sure the specific therapy you’re being offered has data showing it works.